Humacyte
Manufacturing · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2525 E North Carolina Hwy 54, Durham, No...Phone Number
(919) 313-9633Website
www.humacyte.comRevenue
<$5 MillionStock Symbol
HUMAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Explore more
Humacyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Humacyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Humacyte has recently received funding, and reach out quickly before it becomes old news!
Check out if Humacyte is spiking on competitors!
Funding: Get notified immidiatlly once Humacyte has new funding data
Product Launch: Get notified when Humacyte launches new products
Click to see if Humacyte had a recent Job posting/layoffs
Humacyte, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Humacyte
Earning: See what the market has to say on Humacyte recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Humacyte
Compare insights from companies similar to Humacyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Humacyte is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Humacyte is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Humacyte.
Humacyte financials insights
Gather financial insights about Humacyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series B
$150M
2016
Private Equity
$10M
2017
Unspecified
$14.1M
2018
Other Financing Round
$150M
2020
Debt
$2M
2021
Debt
$50M
2023
Debt
$150M
Humacyte Tech Stack
A closer look at the technologies used by Humacyte
See more technologies
Most Recent Scoops
Person-Based
Finance, Financial Transactions
Project
Humacyte has entered into a $1.475 million purchase commitment with the Kingdom of Saudi Arabia to facilitate clinical evaluation and outreach programs for Symvess in hospitals within the kingdom, conducted in parallel with ongoing negotiations with a kingdom-based entity for a joint venture and license to commercialize Symvess in-country.
Business Development, Clinical Operations
Layoffs
Humacyte has announced the layoffs of approximately 45 employees, representing roughly 25% of its workforce, in May 2026 as part of a workforce restructuring effort to reduce costs, enabled by the successful completion of multiple technical and clinical projects.
Layoffs, Clinical Operations
Executive Move
Humacyte has announced that Dr. Todd Rasmussen has been named Chief Surgical Officer at Humacyte. Dr. Rasmussen is recognized as a pioneer in modern vascular surgery, particularly in vascular trauma and peripheral artery disease.
Executive Move
Humacyte News & Media
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston –Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissionsHumacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection withHumacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Humacyte
Sign Up For FreeTo access detailed company insights
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ves... Read More
